A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer

Required: FOLH1 expression

retrospective detection of Prostate-specific membrane antigen (PSMA) expression and other biomarker analysis

Must have received: antiandrogen — novel anti-androgen receptor therapy

Has prior novel anti-androgen receptor therapy failure

Must have received: taxane

had treatment failure with 1-2 taxane-based chemotherapy regimens including for metastatic hormone sensitive prostate cancer

Cannot have received: PSMA radionuclide therapy

Exception: unless participant received <2 cycles

Prior PSMA radionuclide therapy within 2 months prior to GSK5458514 unless participant received <2 cycles

Cannot have received: PSMA CAR-T cell therapy

Prior PSMA-Chimeric antigen receptor T cell therapy (CAR-T) cell therapy

Cannot have received: PSMA T cell engager

PSMA (T cell engager) TCE/ Bispecific T cell engagers (BiTE) or other prostate Tumor-associated antigens (TAA) specific T cell engager (TCE)

Cannot have received: bone marrow transplant

any history of prior allogenic or autologous bone marrow transplant

Cannot have received: solid organ transplant

other solid organ transplant

Cannot have received: systemic biologic therapy

Any anti-cancer therapy or prior systemic biologic therapy, including immunotherapy within 4 weeks of start dose